MD Magazine® Staff

The oral CGRP antagonist becomes the first in its class approved for the indication.

The small molecule orexin receptor antagonist will be made available for the US market in 2 different doses, in 2020.

The approval comes 4 months following a Complete Response Letter was submitted and successfully disputed, to Sarepta Therapeutics.

The FDA approves Botox injections to treat pediatric patients with both upper and lower limb spasticity, unless it was caused by cerebral palsy.

The FDA approves Descovy to reduce the risk of HIV infection through sex.

HIV patients will be allowed to switch to doravirine or doravirine/lamivudine/tenofovir disoproxil fumarate if they are virally suppressed with no prior history of treatment failure.

Former Vice President Joe Biden's presidential campaign has resulted in the nonprofit organization's indefinite suspension.

Lung cancer is currently the deadliest cancer in the US. An online guide and tool provider for physicians could help cut the rate.

Developed as part of a joint partnership between Sanofi and Merck, Vaxelis' commercial supply is not expected until 2020.

The therapy is indicated for ITP patients aged 1 year and older who have been diagnosed for at least 6 months, and have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

After the therapy was approved by the FDA in May, investigators are anticipating its first real-world data will paint a clearer picture of its potential.

The smaller, incomplete study is looking into both the efficacy and safety of the longtime therapy for patients with RA.

Repository corticotropin injection’s nearly six-decade history as a therapy has been tumultuous, but has most recently resulted in its use as an auto-immune drug.

Speaking ambitiously, determining the right tests and initial therapies for patients with rheumatoid arthritis could become optimized.

A 48-year-old man presents with severe atopic dermatitis that he’s had since childhood. Can allergy shots succeed where standard treatments failed?

Research on nonalcoholic fatty liver disease in persons infected with HIV revealed a prevalence of the condition of about 40%.

Medical options can include oral contraceptives, pain medications, hormonal therapies, and gonadotropin-releasing hormone (GnRH) agonists.

How the conflicting results of the ASCEND trial are actually much more determinant than they appear, and critical in the scope of treating comorbidities in patients with diabetes.

Frank Trudo, MD, MBA, was recently appointed as VP, US Respiratory, Medical Affairs, at AstraZeneca.

Catch up on this week's biggest headlines in FDA news.

This week, the FDA received an application for a metoclopramide nasal spray and a receptor agonist for hypoactive sexual desire disorder, approved baricitinib on its second try, and granted Priority Review to emicizumab for hemophilia A.

This podcast series details the ins and outs of managing, preventing, and treating HIV, from the perspective of the faculty and patients of the UNC Institute for Global Health & Infectious Diseases.

This week on MDNN: Cinnamon flavoring in e-cigarettes has been found to disrupt the lungs’ anti-bacterial defense system, new hypertension guidelines have increased the condition's prevalence, and the US Congress passed a right-to-try bill.

This week on MDNN: ADHD symptoms are linked to binge and restrictive eating, physicians paid by opioid marketers are more likely to prescribe them, and one-third of nurses work overtime.

Researchers are using hi-def retinal and neuroimaging techniques to elucidate the relationship between pathology in layers of the retina and downstream brain alterations.

This week on MDNN: Stigmatizing phrasing influences patient care, Pokemon GO improves behavioral health, depressed women and men differentiate in gene expression, and fast food can stall a woman's time to pregnancy.

This week on MDNN: Autism Spectrum Disorder rates are rising in the US, handwashing is effective for C. diff prevention, and PROMISE 1 trial results have been reported.

This week on MDNN: Prolonged use of acetaminophen has been linked to an increase in the relative risk of ADHD and ASD, the ANA annual meeting issued 30 new recommendations for disease-modifying therapy for multiple sclerosis and the American Academy of Family Physicians announced a new Well-Being Planner to manage stressors and address burnout.

This week on MDNN: The SELECT-COMPARE trial reported positive results for upadacitinib, older adults in the US are not being tested for HIV, and the shifting trends in US mortality.